Compare Gogoro Inc (GGR) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gogoro Inc vs Medpace Holdings Inc — how do they compare? Gogoro Inc trades at $3.02 (market cap $56.21M), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 299.2× Gogoro Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Gogoro Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gogoro Inc for 14 Days and Medpace Holdings Inc for 14 Days on average.
| GGR | MEDP | |
|---|---|---|
Market Cap | $56.21M | $16.82B |
Volume | 14,026 | 223,093 |
Sector | Consumer Cyclical | Health |
52-Week High | $5.15 | $630.19 |
52-Week Low | $2.20 | $393.42 |
Typical Hold Time | 14 Days | 14 Days |
Enterprise Value | $342.65M | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GGR trades at $2.99, down 6.27% today, with a bullish technical signal from moving averages but negative profitability metrics including a -16.68% net income margin. Recent developments include new board appointments and a $61.8 million equity investment announced in October 2026. The company shows revenue growth from $281 million in 2025 to $286 million projected for 2026, though net losses persist.
The outlook remains cautious with 100% hold ratings from analysts. Investment appeal lies in the low P/S of 0.18 and EV/EBITDA of 6.38, but risks include sustained negative cash flow and high debt-to-asset ratio of 60%. Positive technical momentum contrasts with fundamental challenges in achieving profitability.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
